Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 62

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 2
Chunk 62
---
 any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership.

Such
conditions raise substantial doubts about the Company’s ability to continue as a going concern. Based on the above, management
has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered
public accounting firm for the year ended December 31, 2024, includes an explanatory paragraph which expresses substantial doubt about
our ability to continue as a going concern. See also Note 2 to the Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Management’s
plan includes private or public equity financings, collaborations, or other strategic transactions such as raising funds from outside
investors via its ATM program and other potential funding sources The Company may not be able to obtain funding on acceptable terms,
or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s
ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside
of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company. If the Company is unable to
obtain sufficient capital to fund its operations it may be required to evaluate alternatives. The Company’s financial statements
do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification
of liabilities that may be required should the Company be unable to continue as a going concern.

As
a result of the risks and uncertainties discussed in the 2024 Annual Report filed on February 27, 2025 with the SEC, among others, we are unable to estimate the duration
and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from
the commercialization and sale of a product if one of our drug candidates receives regulatory approval for marketing, if at all. Our
inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or
our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could
adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease as a
result of many factors, including the extent to which we choose to advance our research and development activities, preclinical
studies and clinical trials, or whether we are